Home > Healthcare > Healthcare Regulatory Affairs Outsourcing Market > Table of Contents

Healthcare Regulatory Affairs Outsourcing Market Size - By Services, By Indication, By Product Stage (Preclinical, Clinical, PMA), By End-use (Pharmaceutical Companies, Biotechnology Companies, Medical Device Companies) & Global Forecast, 2024 – 2032

  • Report ID: GMI8287
  • Published Date: Feb 2024
  • Report Format: PDF

Report Content

Chapter 1   Methodology & Scope

1.1    Market scope & definition

1.2    Base estimates & calculations

1.3    Data collection

1.4    Forecast parameters

1.5    Data validation

1.6    Data sources

1.6.1    Primary

1.6.2    Secondary

1.6.2.1   Paid sources

1.6.2.2   Public sources

Chapter 2   Executive Summary

2.1    Industry 360-degree synopsis

Chapter 3   Industry Insights

3.1    Industry ecosystem analysis

3.2    Industry impact forces

3.2.1    Growth drivers

3.2.1.1   Growing need to comply with regulatory requirements

3.2.1.2   Surging demand for faster approval process for breakthrough drugs and devices

3.2.1.3   Rising number of clinical trials

3.2.1.4   Increasing regulatory complexity

3.2.2    Industry pitfalls & challenges

3.2.2.1   Data security and privacy concerns

3.2.2.2   Lack of standardization

3.3    Growth potential analysis

3.4    Porter's analysis

3.4.1    Supplier power

3.4.2    Buyer power

3.4.3    Threat of new entrants

3.4.4    Threat of substitutes

3.4.5    Industry rivalry

3.5    PESTEL analysis

3.6    Service price analysis

3.7    Regulatory landscape

3.8    Technological landscape

3.9    Future market trends

Chapter 4   Competitive Landscape, 2023

4.1    Introduction

4.2    Company matrix analysis

4.3    Company market share analysis

4.4    Competitive positioning matrix

4.5    Strategy dashboard

Chapter 5   Market Estimates and Forecast, By Services, 2018 – 2032 ($ Mn)

5.1    Key trends

5.2    Product registration & clinical trial application

5.3    Regulatory consulting/strategic services

5.4    Submission management

5.5    Legal representation

5.6    Regulatory writing & publishing

5.7    Other services

Chapter 6   Market Estimates and Forecast, By Indication, 2018 – 2032 ($ Mn)

6.1    Key trends

6.2    Oncology

6.3    Neurology

6.4    Cardiology

6.5    Immunology

6.6    Other indications

Chapter 7   Market Estimates and Forecast, By Product Stage, 2018 – 2032 ($ Mn)

7.1    Key trends

7.2    Preclinical

7.3    Clinical

7.4    Post market authorization (PMA)

Chapter 8   Market Estimates and Forecast, By End-Use, 2018 – 2032 ($ Mn)

8.1    Key trends

8.2    Pharmaceutical companies

8.3    Biotechnology companies

8.4    Medical device companies

Chapter 9   Market Estimates and Forecast, By Region, 2018 – 2032 ($ Mn)

9.1    Key trends

9.2    North America

9.2.1    U.S.

9.2.2    Canada

9.3    Europe

9.3.1    Germany

9.3.2    UK

9.3.3    France

9.3.4    Spain

9.3.5    Italy

9.3.6    Rest of Europe

9.4    Asia Pacific

9.4.1    China

9.4.2    Japan

9.4.3    India

9.4.4    Australia

9.4.5    South Korea

9.4.6    Rest of Asia Pacific

9.5    Latin America

9.5.1    Brazil

9.5.2    Mexico

9.5.3    Argentina

9.5.4    Rest of Latin America

9.6    Middle East and Africa

9.6.1    South Africa

9.6.2    Saudi Arabia

9.6.3    UAE

9.6.4    Rest of Middle East and Africa

Chapter 10   Company Profiles

10.1    Accell Clinical Research, LLC

10.2    Charles River Laboratories

10.3    Clinilabs, Inc.

10.4    Freyr

10.5    Genpact

10.6    ICON plc

10.7    Labcorp Drug Development

10.8    PAREXEL International Corporation

10.9    ProPharma Group

10.10    Proventa International

10.11    Thermo Fisher Scientific Inc.

   

Authors: Mariam Faizullabhoy, Gauri Wani

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 11
  • Tables & Figures: 307
  • Countries covered: 22
  • Pages: 180
 Download Free Sample